We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals

235 hedge funds and large institutions have $2.12B invested in Agios Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 83 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

620% more call options, than puts

Call options by funds: $127M | Put options by funds: $17.6M

85% more capital inflows, than outflows

Capital inflows: $460M | Capital outflows: $249M

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

2.49% more ownership

Funds ownership: 105.18% → 107.67% (+2.5%)

1% less repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 83

3% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 37

2% less funds holding

Funds holding: 239 → 235 (-4)

Holders
235
Holders Change
-4
Holders Change %
-1.67%
% of All Funds
2.85%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.06%
New
36
Increased
82
Reduced
83
Closed
37
Calls
$127M
Puts
$17.6M
Net Calls
+$109M
Net Calls Change
+$22M

AGIO Hedge Fund Activity: Q1 2026 in Review

235 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2026, worth a combined $2.12B — up 27% from $1.67B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of AGIO and 36 opened new positions — a net loss of 1 holder — while 83 trimmed existing stakes and 82 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $71.8M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $32.2M sold.

  • 235 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2026, down from 239 in Q4 2025.
  • Funds reported $2.12B of Agios Pharmaceuticals stock for Q1 2026, up 27% quarter-over-quarter.
  • 36 funds opened new Agios Pharmaceuticals positions in Q1 2026 and 37 closed out, a net change of -1 holder.
  • The largest Agios Pharmaceuticals buyer in Q1 2026 was Lynx1 Capital Management, an estimated $71.8M added.
  • The largest Agios Pharmaceuticals seller in Q1 2026 was TCG Crossover Management, an estimated $32.2M sold.

Based on aggregated 13F filings for Q1 2026.